Hoffmann-La Roche

RocheHoffmann–La RocheHoffman-La RocheRoche PharmaceuticalsHoffman-LaRocheHoffmann-LaRocheF. Hoffmann-La RocheRoche LaboratoriesRoche Holding AGRoche Holding
F. Hoffmann-La Roche AG is a Swiss multinational healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics.wikipedia
607 Related Articles

Genentech

Genentech, Inc.Genentech, Incgene.com
The company controls the American biotechnology company Genentech, which is a wholly owned affiliate, and the Japanese biotechnology company Chugai Pharmaceuticals, as well as the United States-based Ventana.
Genentech, Inc., is a biotechnology corporation which became a subsidiary of Roche in 2009.

Novartis

SandozCiba-GeigyHexal Australia
Descendants of the founding Hoffmann and Oeri families own slightly over half of the bearer shares with voting rights (a pool of family shareholders 45%, and Maja Oeri a further 5% apart), with Swiss pharma firm Novartis owning a further third of its shares.
Novartis AG also holds 33.3% of the shares of Roche however, it does not exercise control over Roche.

Benzodiazepine

benzodiazepinesbenzodiazapinesbenzo
In 1957 it introduced the class of tranquilizers known as benzodiazepines (with Valium and Rohypnol being the best known members).
The first such drug, chlordiazepoxide (Librium), was discovered accidentally by Leo Sternbach in 1955, and made available in 1960 by Hoffmann–La Roche, which, since 1963, has also marketed the benzodiazepine diazepam (Valium).

Ventana Medical Systems

VentanaVentana Medical Systems, Inc.
The company controls the American biotechnology company Genentech, which is a wholly owned affiliate, and the Japanese biotechnology company Chugai Pharmaceuticals, as well as the United States-based Ventana.
Part of the Roche Diagnostics Division, Ventana is a member of the Roche Group.

Roche Diagnostics

Boehringer MannheimRocheRoche Molecular Systems
F. Hoffmann-La Roche AG is a Swiss multinational healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics.
Roche Diagnostics is a diagnostic division of Hoffmann-La Roche which manufactures equipment and reagents for research and medical diagnostic applications.

Redoxon

In 1934, it became the first company to mass-produce synthetic vitamin C, under the brand name Redoxon.
Redoxon was first marketed to the general public by Hoffman-La Roche in 1934, making it the first mass-manufactured synthetic vitamin in history.

Chugai Pharmaceutical Co.

ChugaiChugai PharmaceuticalsChugai Pharma
The company controls the American biotechnology company Genentech, which is a wholly owned affiliate, and the Japanese biotechnology company Chugai Pharmaceuticals, as well as the United States-based Ventana. Roche acquired Syntex in 1994 and Chugai Pharmaceuticals in 2002.
It is a subsidiary controlled by Hoffmann–La Roche, which owns 62% of the company as of 30 June 2014.

Seveso disaster

ICMESASevesoindustrial accident
In 1976, an accident at a chemical factory in Seveso, Italy, owned by a subsidiary of Roche, caused a large dioxin contamination; see Seveso disaster.
The industrial plant, located in Meda, was owned by the company ICMESA (Industrie Chimiche Meda Società Azionaria), a subsidiary of Givaudan, which in turn was a subsidiary of Hoffmann-La Roche (Roche Group).

Fritz Hoffmann-La Roche

Fritz HoffmannMaja Oeri
Founded in 1896 by Fritz Hoffmann-La Roche, the company was early on known for producing various vitamin preparations and derivatives.
Fritz Hoffmann-La Roche, later Fritz Hoffmann-von der Mühll (24 October 1868, Basel (Bâle) – 18 April 1920, Basel) was the founder of Hoffmann-La Roche Ltd. (F.

Nutley, New Jersey

NutleyNutley TownshipNutley, NJ
As a result of the Genentech acquisition, Roche closed its Palo Alto based research facilities and moved them to their campus that straddles the border between Clifton, New Jersey and Nutley, New Jersey while Roche's United States headquarters, located on the site since 1929, was moved to Genentech's facility in South San Francisco.
Nutley had been the U.S. headquarters of Hoffmann-La Roche and was the site of the creations of the medications Valium and Librium, later becoming one of the major R&D sites for Roche, hosting major research areas in oncology, virology and inflammation.

454 Life Sciences

454454 sequencing454 technology
It was acquired by Roche in 2007 and shut down by Roche in 2013 when its technology became noncompetitive, although production continued until mid-2016.

Switzerland

SwissSwiss ConfederationSWI
F. Hoffmann-La Roche AG is a Swiss multinational healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics.
The largest Swiss companies by revenue are Glencore, Gunvor, Nestlé, Novartis, Hoffmann-La Roche, ABB, Mercuria Energy Group and Adecco.

Spark Therapeutics

In February 2019, the business announced it would acquire gene therapy company, Spark Therapeutics, for $4.3 billion ($114.50 per share) adding Spark's gene therapy portfolio to its previous acquired assets.
In February 2019, Roche announced it would acquire the company for $4.3 billion ($114.50 per share).

Moclobemide

Aurorix
It is produced by affiliates of the Hoffmann–La Roche pharmaceutical company.

Flumazenil

AnexateRomazicon
It was first characterized in 1981, and was first marketed in 1987 by Hoffmann-La Roche under the trade name Anexate.

Gilead Sciences

GileadGilead Sciences, Inc.Gilead Sciences, Inc
Roche is the only drug company authorized to manufacture the drug, which was discovered by Gilead Sciences.
Also in 1999, Roche announced first approval of Tamiflu (oseltamivir) for the treatment of influenza.

Alectinib

Alecensa
It was developed by Chugai Pharmaceutical Co. Japan, which is part of the Hoffmann-La Roche group.

Tocilizumab

ActemraActemra (Hoffmann-La Roche/Chugai)
It was developed by Hoffmann–La Roche and Chugai.

Syntex

Syntex CorporationSyntex ResearchSyntex Research Laboratories
Roche acquired Syntex in 1994 and Chugai Pharmaceuticals in 2002.
Syntex was acquired by the Roche group in 1994.

LabCorp

Laboratory Corporation of AmericaLaboratory Corp. of America HoldingLaboratory Corporation of America Holdings
Within 2 years of its approval (and that of ritonavir 4 months later) annual deaths from AIDS in the United States fell from over 50,000 to approximately 18,000 On 28 April 1995 Hoffmann-La Roche sold Roche Biomedical Laboratories, Inc. to National Health Laboratories Holdings Inc. (which then changed its name to Laboratory Corporation of America Holdings).
On April 28, 1995 National Health Laboratories Holdings Inc. merged with Roche Biomedical Laboratories, Inc. and changed its name to Laboratory Corporation of America Holdings.

Obinutuzumab

Gazyvaafutuzumab
Also in 2005, Roche acquired the Swiss company GlycArt Biotechnology in order to acquire technology to afucosylate antibodies; one of its products in development was obinutuzumab, which gained FDA approval in November 2013 for the treatment of chronic lymphocytic leukemia.
Obinutuzumab (called afutuzumab until 2009) is a humanized anti-CD20 monoclonal antibody, originated by GlycArt Biotechnology AG and developed by Roche as a cancer treatment.

Basel

Basel, SwitzerlandBasleBâle
The company headquarters are located in Basel.
Novartis, Syngenta, Ciba Specialty Chemicals, Clariant, Hoffmann-La Roche, Basilea Pharmaceutica and Actelion are headquartered there.

Influenza A virus subtype H5N1

H5N1bird fluavian flu
Oseltamivir is considered to be the primary antiviral drug used to combat avian influenza, commonly known as the bird flu.
There is no highly effective treatment for H5N1 flu, but oseltamivir (commercially marketed by Roche as Tamiflu), can sometimes inhibit the influenza virus from spreading inside the user's body.

GlaxoSmithKline

GlaxoSmithKline BeechamGSK
Established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, GSK was the world's seventh largest pharmaceutical company as of 2015, after Johnson & Johnson, Pfizer, Novartis, Merck, Hoffmann-La Roche and Sanofi.